NOV Inc. Stock
We can see a decrease in the price for NOV Inc.. Compared to yesterday it has lost -€0.300 (-1.730%).
Currently there is a rather positive sentiment for NOV Inc. with 18 Buy predictions and 4 Sell predictions.
With a current price of 17.0 € NOV Inc. is right around the predicted target price of 17 €.
Our community identified positive and negative aspects for NOV Inc. stock for the coming years. 1 users see the criterium "Balance Sheet Risk" as a plus for the NOV Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of NOV Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of NOV Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| NOV Inc. | -1.730% | 5.590% | 1.040% | 57.919% | 28.205% | 0.000% | 57.407% |
| SBM Offshore N.V. | 2.360% | 7.647% | 4.069% | 105.314% | 48.245% | 180.680% | 162.712% |
| Cimc Enric Holdings Inc. | -1.870% | -5.405% | -10.256% | 61.538% | 8.808% | 31.250% | 45.833% |
| Core Laboratories Inc. | -0.690% | 2.878% | 6.716% | 41.584% | 5.147% | -28.141% | -35.000% |
Comments
NOV (NOV) had its price target raised by Stifel Nicolaus from $21.00 to $23.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NOV provided by MarketBeat
NOV (NOV) had its price target raised by Susquehanna from $21.00 to $22.00. They now have a "positive" rating on the stock.
Show more
Ratings data for NOV provided by MarketBeat
NOV (NOV) had its price target raised by The Goldman Sachs Group, Inc. from $17.00 to $20.00. They now have a "sell" rating on the stock.
Show more
Ratings data for NOV provided by MarketBeat
News
This Fund Put 22% of Assets Into an Oilfield Equipment Stock Up 25% in a Year
London-based Oldfield Partners increased its stake in NOV (NYSE:NOV) by 276,961 shares in the fourth quarter, an estimated $4.11 million trade based on quarterly average pricing, according to a
